14 November 2025 In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that tools remain prone to ‘confident’ errors, writes Marisa Woutersen.
13 November 2025
13 November 2025
11 November 2025
11 November 2025
Latest Features
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
From setting a clear overall strategy to drafting high-quality claims, Christopher Wheeler and Gerald Murphy of Birch, Stewart, Kolasch & Birch explain how to reduce patent prosecution expenditure and obtain better IP protection.
Asia
Hui Zhuang of CCPIT Patent and Trademark Law Office discusses several strategies to increase the chance of pharmaceutical or food trademarks that include ingredients being registered.
More News
10 November 2025 According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.
7 November 2025 The ‘distinguished litigator’ rejoins six former colleagues at the new firm, bringing expertise in high-stakes disputes representing global tech and life sciences clients.
7 November 2025 Sister title WIPR’s China Patent Rankings detail the firms and individuals most capable of handling patent matters in the country, from litigators with winning streaks to global strategists.
6 November 2025 Judge delivers major setback to pharma giant’s efforts to scupper rival’s surprise bid, in an increasingly bitter feud over an obesity drug biotech.
6 November 2025 Womble Bond Dickinson has expanded its West Coast footprint with the addition of a seasoned patent litigator, strengthening the firm’s life sciences capabilities amid rising IP disputes and rapid biotech innovation.
6 November 2025 Barley Snyder partner Sal Anastasi—woodworker, pilot, and now head of the AIPLA—speaks to WIPR about the urgent need for clarity in patent eligibility, and why collaboration and engagement are essential as the USPTO ushers in a period of rapid change.
4 November 2025 Growing clout, powerful remedies, and efficiency are making the UPC a game-changer in global litigation, according to LSPN Europe experts. Tom Phillips reports.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox